IPOs and Catalysts/Events, Global Equity Research Ltd

Arun George

IPOs and Catalysts/Events

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

Equity Capital Markets

Everest Medicines / Equity Capital Markets

<p><a href="https://www.smartkarma.com/entities/everest-medicines" target="_blank" data-smartkarma-citation="entities:29224:1" rel="noopener">Everest Medicines (EVEREST HK)</a> is a biopharmaceutical company which targets four therapeutic areas - oncology, immunology, cardio-renal disease and infectious disease. Everest has launched a Hong Kong IPO to raise net proceeds of HK$3,132.4 million ($404 million) at the mid-point of the IPO price range. At the IPO price range, Everest will command a market cap of HK$14,185-15,603 million ($1.8-2.0 billion).</p><div class="content-highlight"><p>Everest’s strategy is to identify post-proof-of-concept stage assets with a favourable risk-reward potential in China. Everest has a broad drug pipeline with significant near-term revenue potential from 2021/2022. Overall, we believe that the prospectus Everest’s anchor drug assets in their respective therapeutic areas are favourable. </p></div>

Everest Medicines (EVEREST HK) is a biopharmaceutical company which targets four therapeutic areas - oncology, immunology, cardio-renal disease and infectious disease. Everest has launched a Hong Kong IPO to raise net proceeds of HK$3,132.4 million ($404 million) at the mid-point of the IPO price range. At the IPO price range, Everest will command a market cap of HK$14,185-15,603 million ($1.8-2.0 billion).Everest’s strategy is to identify post-proof-of-concept stage assets with a favourable risk-reward potential in China. Everest has a broad drug pipeline with significant near-term revenue potential from 2021/2022. Overall, we believe that the prospectus Everest’s anchor drug assets in their respective therapeutic areas are favourable. 

Everest Medicines IPO Initiation: Potent Medicine

United States

Tetraphase Pharmaceuticals, Inc. biopharmaceutical products. The Company offers antibiotics to treat multi-drug resistant bacterial infections. Tetraphase Pharmaceuticals serves patients in the United States.

Tetraphase Pharmaceuticals (TTPH US)

Everest Medicines IPO Initiation: Potent Medicine

Everest Medicines Everest Medicines (EVEREST HK) is a biopharmaceutical company which targets four therapeutic areas - oncology, immunology,...

Arun George